Skip to main content
. 2022 Jan 19;81(4):524–536. doi: 10.1136/annrheumdis-2021-220873

Figure 6.

Figure 6

Mavrilimumab impacts macrophage functions. (A) Transcript levels of IL-6 (left), TNFα (central) and IL-1β (right) in GCA-positive arteries (n=11) exposed to placebo or mavrilimumab (mRNA, relative units). IL-6, tumour necrosis factor α (TNFα) and IL-1β proteins (pg/mL) were also measured in GCA artery culture supernatants of the same samples. (B) CD206, CD163 and IL-10 mRNA transcript levels in the same GCA arteries exposed to mavrilimumab or placebo. IL-10 protein (pg/mL) was also detected in the supernatant (right panel). GCA, giant cell arteritis; IL, interleukin.